[go: up one dir, main page]

NO20080150L - Inhibitorer av AKT-aktivitet - Google Patents

Inhibitorer av AKT-aktivitet

Info

Publication number
NO20080150L
NO20080150L NO20080150A NO20080150A NO20080150L NO 20080150 L NO20080150 L NO 20080150L NO 20080150 A NO20080150 A NO 20080150A NO 20080150 A NO20080150 A NO 20080150A NO 20080150 L NO20080150 L NO 20080150L
Authority
NO
Norway
Prior art keywords
akt activity
inhibitors
akt
compounds
inhibit
Prior art date
Application number
NO20080150A
Other languages
English (en)
Inventor
Jiabing Wang
Donna J Armstrong
Essa H Hu
Michael J Kelly Iii
Mark E Layton
Yiwei Li
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Philip E Sanderson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20080150L publication Critical patent/NO20080150L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer substituerte naftyridinforbindelser ifølge formel I, som inhiberer Akt-aktivitet. Særlig inhiberer de beskrevne forbindelser selektivt én eller to av Akt-isoformene. Oppfinnelsen tilveiebringer også preparater som omfatter slike inhibitorforbindelser, og fremgangsmåter for inhibering av Akt-aktivitet ved å administrere forbindelsen til en pasient som trenger behandling for kreft. (I)
NO20080150A 2005-06-10 2008-01-09 Inhibitorer av AKT-aktivitet NO20080150L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07
PCT/US2006/022079 WO2006135627A2 (en) 2005-06-10 2006-06-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
NO20080150L true NO20080150L (no) 2008-03-10

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080150A NO20080150L (no) 2005-06-10 2008-01-09 Inhibitorer av AKT-aktivitet

Country Status (22)

Country Link
US (1) US8008317B2 (no)
EP (1) EP1898903B8 (no)
JP (1) JP5055494B2 (no)
KR (1) KR100959771B1 (no)
AU (1) AU2006258124B8 (no)
BR (1) BRPI0611717A2 (no)
CA (1) CA2610888C (no)
CR (1) CR9580A (no)
DK (1) DK1898903T3 (no)
EC (1) ECSP077980A (no)
ES (1) ES2409168T3 (no)
HR (1) HRP20130429T1 (no)
IL (1) IL187690A (no)
MX (1) MX2007015578A (no)
NI (1) NI200700320A (no)
NO (1) NO20080150L (no)
NZ (1) NZ563423A (no)
PL (1) PL1898903T3 (no)
PT (1) PT1898903E (no)
RU (1) RU2421454C2 (no)
TW (1) TW200800166A (no)
WO (1) WO2006135627A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510823A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害剤
PL1898903T3 (pl) 2005-06-10 2013-08-30 Merck Sharp & Dohme Inhibitory aktywności Akt
TW200806670A (en) 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
EP2120951A4 (en) * 2006-12-06 2012-02-15 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US20100029697A1 (en) * 2007-03-28 2010-02-04 Debenham John S Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US7776864B2 (en) 2007-08-14 2010-08-17 Bayer Schering Pharma Ag Fused bicyclic pyrimidines
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2011522048A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8809547B2 (en) 2008-07-17 2014-08-19 Bayer Cropscience Ag Heterocyclic compounds as pesticides
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
SG172898A1 (en) 2009-02-13 2011-08-29 Bayer Schering Pharma Ag Fused pyrimidines
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
WO2010101734A1 (en) * 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
EP2406250B1 (en) * 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
EP2513059A4 (en) * 2009-12-17 2013-06-05 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2012007345A2 (en) * 2010-07-12 2012-01-19 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrimidines and -pyridines
JP5996532B2 (ja) * 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
JO3068B1 (ar) 2011-04-07 2017-03-15 Bayer Ip Gmbh إيميدازوبيريميدينات كمثبطات كيناز akt
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104471070B (zh) * 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
BR112015017331B1 (pt) 2013-01-23 2022-01-11 Astrazeneca Ab Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
MX2016001901A (es) 2013-08-12 2016-10-13 Tokai Pharmaceuticals Inc Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
EP3091016A1 (en) * 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
JP6630844B2 (ja) * 2015-12-07 2020-01-15 蘇州信諾維医薬科技有限公司Ｓｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ５員複素環式アミド系ｗｎｔ経路阻害剤
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020533317A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 特異的ａｋｔ３活性化剤およびその使用
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
KR20240116621A (ko) * 2021-11-05 2024-07-29 조지아뮨 인코포레이티드 Akt3 조절제
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
JP3107827B2 (ja) * 1995-06-06 2000-11-13 ファイザー・インコーポレーテッド トリサイクリック５，６−ジヒドロ−９Ｈ−ピラゾロ［３，４−ｃ］−１，２，４−トリアゾロ［４，３−ａ］ピリジン類
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
CA2442270C (en) 2001-04-10 2009-09-08 Merck & Co., Inc. Inhibitors of akt activity
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2481229C (en) 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
JP4394961B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤としての融合キノキサリン誘導体
US20050130977A1 (en) 2002-04-08 2005-06-16 Lindsley Craig W. Inhibitors of akt activity
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003288899B2 (en) * 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
ATE503483T1 (de) 2002-10-30 2011-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
WO2004096135A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
AU2004233827B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2522431A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
AU2004233826B2 (en) 2003-04-24 2009-08-13 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
JP2007532551A (ja) 2004-04-09 2007-11-15 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
JP2008510823A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害剤
US20080015212A1 (en) 2004-12-02 2008-01-17 Barnett Stanley F Inhibitors Of Akt Activity
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
WO2006091395A2 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
CA2602197A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
PL1898903T3 (pl) 2005-06-10 2013-08-30 Merck Sharp & Dohme Inhibitory aktywności Akt
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
ES2409168T3 (es) 2013-06-25
PT1898903E (pt) 2013-06-28
PL1898903T3 (pl) 2013-08-30
JP5055494B2 (ja) 2012-10-24
MX2007015578A (es) 2008-03-06
EP1898903A2 (en) 2008-03-19
AU2006258124B2 (en) 2009-09-03
IL187690A0 (en) 2008-11-03
RU2421454C2 (ru) 2011-06-20
WO2006135627A3 (en) 2008-07-31
KR100959771B1 (ko) 2010-05-28
DK1898903T3 (da) 2013-07-01
AU2006258124B8 (en) 2010-01-07
NI200700320A (es) 2008-06-17
KR20080016627A (ko) 2008-02-21
EP1898903B1 (en) 2013-03-27
EP1898903B8 (en) 2013-05-15
CA2610888A1 (en) 2006-12-21
WO2006135627A2 (en) 2006-12-21
CR9580A (es) 2008-09-23
RU2008100045A (ru) 2009-07-20
TW200800166A (en) 2008-01-01
HRP20130429T1 (en) 2013-06-30
BRPI0611717A2 (pt) 2009-01-13
AU2006258124A1 (en) 2006-12-21
JP2009501698A (ja) 2009-01-22
ECSP077980A (es) 2008-01-23
US20100222321A1 (en) 2010-09-02
NZ563423A (en) 2010-05-28
IL187690A (en) 2012-06-28
EP1898903A4 (en) 2010-07-21
US8008317B2 (en) 2011-08-30
CA2610888C (en) 2011-02-08

Similar Documents

Publication Publication Date Title
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20092569L (no) Inhibitorer av Akt-aktivitet
WO2006091395A3 (en) Inhibitors of akt activity
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20061194L (no) Mitotiske kinesininbibitorer
NO20081454L (no) Met-kinaseinhibitorer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200970486A1 (ru) Соединения для ингибирования митоза
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20091605L (no) Pyridinonforbindelser
NO20080785L (no) Behandling av kreft
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
DE60329326D1 (de) Tace inhibitoren
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
WO2006068796A3 (en) Inhibitors of akt activity
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application